Clifford Pyne
Acute Care · Olean, NYNPI 1245306729
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 234 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $2,052 and has fallen 54.8% since, to $927 in 2025. Among acute care clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 234 payments — averaging $27.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$773
- Edwards Lifesciences$664
- Amgen$641
- Johnson & Johnson$612
- Boehringer Ingelheim$599
- Novartis$548
- plus $3K from 20 others
What the payments were for
- Food & beverage$6,522100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 22 | $773 |
| Edwards Lifesciences | 13 | $664 |
| Amgen | 29 | $641 |
| Johnson & Johnson | 16 | $612 |
| Boehringer Ingelheim | 31 | $599 |
| Novartis | 39 | $548 |
| Medtronic | 13 | $405 |
| Alnylam Pharmaceuticals Inc. | 7 | $340 |
| Pfizer | 13 | $329 |
| Phathom Pharmaceuticals, Inc. | 2 | $249 |
| Boston Scientific | 7 | $228 |
| Novo Nordisk | 6 | $180 |
| Merck | 9 | $147 |
| Cvrx, Inc. | 1 | $145 |
| Bayer | 7 | $133 |
| E.r. Squibb & Sons, L.L.C. | 1 | $115 |
| Janssen Scientific Affairs, LLC | 1 | $97 |
| Sanofi-aventis U.S. LLC | 3 | $64 |
| Abiomed | 2 | $51 |
| Lexicon Pharmaceuticals, Inc. | 3 | $46 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $45 |
| Esperion Therapeutics, Inc. | 2 | $26 |
| Abbott | 1 | $25 |
| Lilly USA, LLC | 1 | $23 |
| Bridgebio Pharma, Inc. | 1 | $21 |
| Scpharmaceuticals Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$386
- AMVUTTRA$272
- VOQUEZNA$249
- FARXIGA$227
- Barostim Neo System$145
- RYBELSUS$125
- Repatha$125
- WATCHMAN Access System$115
- CAMZYOS$115
- LOKELMA$108
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$106
- VYNDAQEL$100
- Edwards SAPIEN 3 Transcatheter Heart Valve$100
How this compares
$6,522 in reported general payments places this provider in the 95th percentile of 980 acute care providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 679 | $694,336 |
| EntrestoSacubitril/Valsartan | 335 | $375,661 |
| FarxigaDapagliflozin Propanediol | 196 | $241,425 |
| JardianceEmpagliflozin | 194 | $215,069 |
| XareltoRivaroxaban | 190 | $198,505 |
| Repatha SureclickEvolocumab | 134 | $87,424 |
| MultaqDronedarone Hcl | 29 | $34,348 |
| Praluent PenAlirocumab | 30 | $18,382 |
| Metoprolol Succinate | 962 | $16,871 |
| CorlanorIvabradine Hcl | 16 | $15,670 |
| Rosuvastatin Calcium | 656 | $11,850 |
| Repatha SyringeEvolocumab | 16 | $8,796 |
| Ranolazine ErRanolazine | 69 | $6,979 |
| Ezetimibe | 370 | $6,728 |
| Atorvastatin Calcium | 619 | $6,485 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $329 | $694,336679 claims |
| NovartisEntresto | $548 | $375,661335 claims |
| AstraZenecaFarxiga | $773 | $241,425196 claims |
| Boehringer IngelheimJardiance | $599 | $215,069194 claims |
| Johnson & JohnsonXarelto | $612 | $198,505190 claims |
| Sanofi-aventis U.S. LLCMultaq | $64 | $34,34829 claims |
| AmgenCorlanor | $641 | $15,67016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 980 acute care providers in New York.
Other acute care in Olean
- Daniel VerinaNew York$464K
- Michele BiscossiSaratoga Springs$64K
- Heidi YipCanandaigua$29K
- Katie WorthingtonNew York$25K
- Loveth AdenugaNew York$20K
- Katherine DukeNew York$18K
- Ann HarrisBrooklyn$14K
- Marcel RozarioMedina$10K
- Julie Anne RoldanNew York$10K
- Dana SiscoSuffern$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.